BC Week In Review | Apr 5, 2019
Clinical News

Sotio's DCVAC/OvCa improves survival in Phase II for recurrent ovarian cancer

Sotio reported March 19 that DCVAC/OvCa as second-line treatment decreased the risk of death by 62% in the Phase II SOV02 trial to treat recurrent, platinum-sensitive epithelial ovarian cancer. DCVAC/OvCa is an active cellular immunotherapy...
BC Week In Review | Jun 1, 2018
Clinical News

Sotio reports PFS data from Phase II of ovarian cancer immunotherapy

Sotio a.s. (Prague, Czech Republic) reported interim data from the Phase II SOV01 trial to treat epithelial ovarian carcinoma showing that first-line treatment with DCVAC/OvCa given sequentially after carboplatin and paclitaxel significantly improved median progression-free...
BC Week In Review | Dec 8, 2017
Clinical News

Sotio begins Ph II for second-line ovarian cancer candidate

Sotio a.s. (Prague, Czech Republic) began the open-label Phase II SOV06 trial evaluating immunotherapy candidate DCVAC/OvCa as a second-line treatment in combination with standard of care chemotherapy in 30 patients with relapsed platinum-sensitive epithelial ovarian...
BC Week In Review | Jun 9, 2014
Clinical News

DCVAC/PCa: Phase III started

Sotio a.s. , Prague, Czech Republic   Product: DCVAC/PCa   Business: Cancer   Molecular target: NA   Description: Active cellular immunotherapy for prostate cancer that uses a patient's dendritic cells to induce an immune reaction against...
Items per page:
1 - 4 of 4